Please try another search
Icosavax, Inc. (Nasdaq: ICVX) today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 8,369,754 shares of its common stock at a...
Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial...
Investing.com - Icosavax (NASDAQ: ICVX) reported first quarter EPS of $-0.60, $0.01 better than the analyst estimate of $-0.61. Revenue for the quarter came in at $100K versus the consensus estimate...
Investing.com - Icosavax (NASDAQ: ICVX) reported first quarter EPS of $-0.59, $0.10 better than the analyst estimate of $-0.69. Revenue for the quarter came in at $459K versus the consensus estimate...
Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial...
After-Hours Movers: Vera Therapeutics Inc (NASDAQ:VERA) 62% LOWER; announced the Phase 2b ORIGIN clinical trial of atacicept in patients with immunoglobulin A nephropathy (IgAN) met its primary...
Investing.com - Icosavax reported on Monday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations. Icosavax announced earnings per share of $-0.41 on...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review